Medpace is a global contract research organisation (‘CRO’) providing management services to the R&D departments of pharmaceutical, biotech and medical device clients to help plan and oversee their clinical trials. It is committed to providing the most streamlined and cost-effective path to drug and device approval for its sponsors. Medpace focuses on small to mid-size companies and is known for its significant expertise in numerous therapeutic areas such as metabolic, cardiovascular, hematology and oncology, infectious diseases and vaccines, pediatrics, neurology and psychiatry, and nephrology.

Established in 1992, Medpace is headquartered in Cincinnati, Ohio, and has global operations in more than 35 countries, with a significant portion of its clinical operations and employees based in Europe. Medpace is listed on the US NASDAQ Global Select Market.